Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Initiator Pharma A/S (INIT.ST)
Copenhagen, DK
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.19% | -6.80% | -9.72% | -9.72% | +4.73% | -5.26% | -26.15% | -51.35% | -31.43% | -40.41% | -40.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+0.0% Q1'26: -239.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— ★
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-333.8% Q1'26: -780.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+108,682.9% Q1'26: +21.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
est: 138.86M (-100.0%)
|
—
est: 50.18M (-100.0%)
|
53.97M
53.97M – 53.97M
+7.6% YoY
|
66.40M
66.40M – 66.40M
+23.0% YoY
|
11.67M
11.67M – 11.67M
-82.4% YoY
|
| EBITDA |
-14.5K
|
-18.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.5K
|
-18.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-12.9K
est: -18.07M (+99.9%)
|
-14.01M
est: -15.45M (+9.3%)
|
-39.66M
-39.66M – -39.66M
-156.7% YoY
|
25.12M
-78.61M – 37.06M
+163.3% YoY
|
-27.70M
-27.70M – -27.70M
-210.3% YoY
|
| SGA |
3.4K
|
-2.95M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.23
est: -0.29 (+20.7%)
|
-0.23
est: -0.25 (+8.1%)
|
-0.64
-0.64 – -0.64
-154.5% YoY
|
-0.33
-1.26 – 0.59
+47.6% YoY
|
-0.44
-0.44 – -0.44
-33.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Claus Elsborg Olesen | Co-Founder, Chief Executive Officer & Director | 1M | — |
| Dan Peters | Co-Founder & Chief Technology Officer | — | — |
| Mikael Thomsen | Co-Founder & Chief Development Officer | — | — |
| Rene Egebro | Head of CMC | — | male |
| Susanne Thomsen | Head of Clin Ops | — | — |
| Torgeir Vaage | Chief Financial Officer | — | — |
| Allan Wehnert | Senior Vice President of Clinical and R&D Strategy & Portfolio Management | — | — |
| Ulf Simonsen | Co-Founder, CMO & CSO | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INIT.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
